It was once believed that medications could not pass from mother to child, a myth spectacularly exploded by the widespread taking of thalidomide prescribed for morning sickness, insomnia, colds and headaches which resulted in many thousands of infant deaths and disability (in the 1950s the toxicity of thalidomide was tested on animals, but not pregnant women)
Considering this information, dosing a 1:1 blend of BPC-157 + TB-500 at 1mcg/kg daily (0.5mcg/kg each) may be a decent starting point for most researchers
Manufactured in the United States under strict quality standards , this dual-peptide research compound is formulated for investigators studying: Connective tissue response Muscle recovery mechanisms Tendon and ligament research models Angiogenesis signaling pathways Cellular migration and repair processes Inflammatory modulation research Why Combine BPC-157 and TB-500
Meanwhile, a UK survey revealed a growing acceptance of these medications among adults
It is particularly dependent on the activity of several enzymes but this activity can be inhibited rendering these enzymes inactive